Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease
JAMA Network Open · 20.05.2025 · 8 (5) · e2511297
DOI: 10.1001/jamanetworkopen.2025.11297 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 20.05.2025. Verfasst von Sang Hyun Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Clopidogrel, Myocardial Infarction, Platelet Aggregation Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Chronic kidney disease (CKD) is a significant risk factor for both ischemic and bleeding complications following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Optimizing dual antiplatelet therapy (DAPT) is essential for improving clinical outcomes.
Objective
To evaluate whether an 11-month, unguided deescalation strategy from ticagrelor to clopidogrel was associated with reduced bleeding without an increase in ischemic events in stabilized patients with CKD after AMI. Design, Setting, and Participants This was a post hoc secondary analysis of the multicenter, open-label, Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) randomized clinical trial conducted at 32 major cardiac centers in South Korea. Patients with biomarker-positive AMI who tolerated 1 month of ticagrelor-based DAPT after PCI were included in the trial. Patient enrollment occurred from February 2014 to December 2018, with follow-up at 30 days and 3, 6, and 12 months after PCI. The present analysis focused on the subgroup of patients with CKD (estimated glomerular filtration rate [eGFR]<60 mL/min/1.73 m 2 ). Data analyses were performed from July 2023 to October 2024.
Interventions
In the TALOS-AMI trial, patients were randomized 1:1 to continue ticagrelor (active control group) or switch to clopidogrel (deescalation group) for 11 months after PCI. Main Outcomes and Measures The primary end point was a composite of death from cardiovascular disease, myocardial infarction, stroke, and bleeding (Bleeding Academic Research Consortium [BARC] types 2, 3, or 5).
Results
Of 2646 patients included in the trial, 305 had CKD (11.5%; mean [SD] age, 67.2 [11.4] years; 223 males [73.1%]; mean [SD] eGFR, 49.7 [9.5] mL/min/1.73 m 2 ) and 2341 did not have CKD (1975 male [84.4%]; mean [SD] age, 59.0 [11.0] years). Patients with CKD had an increased risk of ischemic events compared with patients without CKD (hazard ratio [HR], 2.47; 95% CI, 1.38-4.42; P = .002), but there was no difference in bleeding risk (HR, 1.36; 95% CI, 0.80-2.31; P = .26). Among patients with CKD, deescalation (n = 160) vs active control (n = 145) was associated with reduced risks of the primary end point (10 patients [6.2%] vs 19 [13.1%]; HR, 0.45 [95% CI, 0.21-0.98]; P = .04) and BARC 2, 3, or 5 bleeding (4 patients [2.5%] vs 12 [8.3%]; HR, 0.29 [95% CI, 0.09-0.89]; P = .03). No increased risk of ischemic events was observed following deescalation (7 patients [4.4%] vs 8 [5.5%]; HR, 0.78 [95% CI, 0.28-2.16]; P = .64). Conclusions and Relevance In this secondary analysis of a randomized clinical trial, deescalation from ticagrelor to clopidogrel at 1 month after PCI for AMI was associated with significant reduction in bleeding without increased risk of ischemic events among study-eligible patients with CKD. Further adequately powered studies are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, The Armed Forces Capital Hospital, Seongnam, Republic of Korea.
- Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Incheon St Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Uijeongbu St Mary's Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea.
Zitieren
APA
Kim, S. H., Lee, K. Y., Byeon, J., Sa, Y. K., Hwang, B. H., Kim, C. J., Choo, E. H., Lim, S., Choi, I. J., Choi, Y. S., Park, C. S., Park, M. W., Her, S. H., Lee, M., Chang, K., & TALOS-AMI Investigators (2025). Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease. JAMA Network Open, 8(5), e2511297. https://doi.org/10.1001/jamanetworkopen.2025.11297
Vancouver
Kim SH, Lee KY, Byeon J, Sa YK, Hwang BH, Kim CJ, et al. Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease. JAMA Network Open. 2025;8(5):e2511297. doi:10.1001/jamanetworkopen.2025.11297
BibTeX
@article{Kim2025,
author = {Kim, Sang Hyun and Lee, Kwan Yong and Byeon, Jaeho and Sa, Young Kyoung and Hwang, Byung-Hee and Kim, Chan Joon and Choo, Eun-Ho and Lim, Sungmin and Choi, Ik Jun and Choi, Yun Seok and Park, Chul Soo and Park, Mahn-Won and Her, Sung-Ho and Lee, Myunhee and Chang, Kiyuk and TALOS-AMI Investigators, TALOS-AMI Investigators},
title = {Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {5},
pages = {e2511297},
doi = {10.1001/jamanetworkopen.2025.11297}
}
EUVIMED